| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CP2CI; CPCI; CYPIIC18; EC 1.14.14.1; P450-6B/29C |
| Entrez GeneID | 1562; |
| WB Predicted band size | 60kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human Cytochrome P450 2C8/9/18/19. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Cytochrome P450 2C8/9/18/19抗体的部分文献示例(注：Cytochrome P452可能为笔误，实际应为P450;2C18研究较少，暂以相关亚型替代)：
---
1. **"Characterization of a novel monoclonal antibody against human cytochrome P450 2C8"**
- 作者：Zhou et al. (2015)
- 摘要：该研究开发了一种特异性识别CYP2C8的单克隆抗体，验证了其在肝组织中的表达检测能力，并应用于药物代谢相互作用分析。
2. **"Immunochemical analysis of cytochrome P450 2C9 polymorphism in human liver microsomes"**
- 作者：García-Martín et al. (2002)
- 摘要：通过特异性抗体检测不同人群肝微粒体中CYP2C9的遗传多态性，揭示其与华法林代谢个体差异的关联。
3. **"Development of a sensitive ELISA for CYP2C19 using a polyclonal antibody"**
- 作者：Tanaka et al. (2010)
- 摘要：报道了一种基于多克隆抗体的ELISA方法，用于定量人血浆中CYP2C19水平，支持临床药物基因组学研究。
4. **"Cross-reactivity of anti-CYP2C antibodies: Implications for phenotyping assays"**
- 作者：Belle & Leroux (2008)
- 摘要：评估了多种CYP2C亚型抗体(包括2C9/19)的特异性，发现部分抗体存在交叉反应，强调抗体验证在代谢酶分型中的重要性。
---
**说明**：
- 实际文献需通过PubMed或Web of Science等平台检索，以上为模拟示例。
- CYP2C18研究较少，可能与2C19存在交叉引用，建议结合具体研究方向筛选文献。
Cytochrome P450 (CYP) enzymes, particularly the CYP2C subfamily (including CYP2C8. CYP2C9. CYP2C18. and CYP2C19), play critical roles in metabolizing xenobiotics, drugs, and endogenous compounds. These hepatic enzymes are involved in phase I drug metabolism, facilitating oxidation reactions that enhance compound solubility for excretion. CYP2C8 is notable for metabolizing taxanes, repaglinide, and some statins, while CYP2C9 handles NSAIDs, warfarin, and hypoglycemic agents. CYP2C19 is key in proton pump inhibitor and clopidogrel metabolism, with genetic polymorphisms affecting drug efficacy and toxicity. CYP2C18. though less studied, may overlap in substrate specificity with other isoforms.
Antibodies targeting CYP2C8/9/18/19 are essential tools for studying enzyme expression, localization, and activity in tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding research on interindividual variability in drug metabolism due to genetic, environmental, or disease-related factors. Such antibodies also support clinical investigations into drug-drug interactions, pharmacogenomics, and personalized medicine. For example, identifying CYP2C19 poor metabolizers helps optimize antiplatelet therapy. Challenges include cross-reactivity due to high sequence homology among CYP2C isoforms, necessitating rigorous validation. These antibodies underpin both basic research and translational studies, bridging mechanistic insights and therapeutic applications in pharmacology and toxicology.
×
